KRAS and Patent ductus arteriosus: Overall, several targetable GAs and ICPIs positive predictive markers were more frequent in KRAS wild-type PDA. This combined with the fact that TP53 alterations were much lower in KRAS wild-type PDA provides sound evidence that this distinct molecular subtype of PDA has the potential to achieve a much better survival outcome.